Figure 5:

reduced numbers of spleen cells in SKI-O-703-treated NZB/W mice. Female NZB/W F1 mice were administrated orally with 42 mpk SKI-O-703 (SKI 42), 84 mpk SKI-O-703 (SKI 84), or tofacitinib (Tofa) from 18 to 34 weeks of age. Spleens and sera were collected at 34 weeks of age. (A–D) Spleens were assayed by FACS. The gating strategy is displayed in Supplementary Fig. S2. (E) Spleens were cryosectioned, stained with Abs to GL-7, IgD, and CD4, and analyzed by confocal microscopy. Two representative images per group are shown. Bar scale, 80 μm. Percentage of GC area (area of GL7⁺/area of total area) from 3 to 4 images/group are displayed as mean ± SD. (F) Splenic B cells were assayed by quantitative RT-PCR. Levels of BAFFR mRNA were normalized to the level of β-actin mRNA. (G) Concentrations of BAFF measured by ELISA in sera. The data are representative of at least two independent experiments. Graphs show means + SEMs, and symbols represent values of individual mice. *P < 0.05 and **P < 0.01 by two-tailed unpaired Students t-test.